Journal profile · ONCOLOGY
Cancer Research and Treatment
ISSN 1598-2998 · eISSN 2005-9256 · Korean Cancer Association · SOUTH KOREA
Cancer Research and Treatment: CAS Zone 2 · Medicine (2025 upgraded edition); impact factor 4.16; fully open access; APC about USD 600; median 123 days to acceptance (81 articles, last 24 months); community-reported acceptance: fairly easy; 164 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Cancer Research and Treatment is published by Korean Cancer Association and is in Zone 2 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Lung Cancer Treatments and Mutations, Gastric Cancer Management and Outcomes and Lung Cancer Diagnosis and Treatment, together about 21.3% of its articles. Its main subfields are Pulmonary and Respiratory Medicine and Oncology. (generated from OpenAlex topic counts and CAS ranking data)
Cancer Research and Treatment is a peer-reviewed open access publication of the Korean Cancer Association, Korean Society of Medical Oncology, and Korean Association for Lung Cancer. It is published quarterly. Abbreviated title is Cancer Res Treat. It accepts manuscripts relevant to experimental and clinical cancer research. Subjects include carcinogenesis, tumor biology, molecular oncology, cancer genetics, tumor immunology, epidemiology, predictive markers and cancer prevention, pathology, cancer diagnosis, screening and therapies including chemotherapy, surgery, radiation therapy, immunotherapy, gene therapy, multimodality treatment and palliative care. Cancer Research and Treatment (CRT) is indexed/tracked/covered by SCI, Medline, PubMed, PubMed Central, KoreaMed, CrossRef, Chemical Abstracts Service (CAS), SCOPUS, KoMCI, and Google Scholar.
From the journal's Aims & Scope
Research area (LetPub): ONCOLOGY
Editor-in-chief Hye SeungPublisher website
Editorial board by country: 1 in mainland China (about 3%); most named South Korea 21, United States 4, Japan 2, Mainland China 1, India 1 (29 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Lung Cancer Treatments and MutationsMedicine8.3%
- Gastric Cancer Management and OutcomesMedicine6.5%
- Lung Cancer Diagnosis and TreatmentMedicine6.5%
- Lung Cancer Research StudiesMedicine5.8%
- Breast Cancer Treatment StudiesBiochemistry, Genetics and Molecular Biology5.7%
- Global Cancer Incidence and ScreeningMedicine5.1%
- Head and Neck Cancer StudiesMedicine4.8%
- Colorectal Cancer Treatments and StudiesMedicine4.8%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 2
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 2 |
| Minor | Oncology | Zone 3 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Oncology | Zone 3 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 2
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 2 |
| Minor | Oncology | Zone 3 |
Top journal: noReview journal: no
Database indexing
SCIEScopusLetPub
International journal early-warning lists: not listed in any editionLetPub
Indexing the journal's website claims
MEDLINEPMCCASPublisher website
Other: Google Scholar, Crossref
As the journal's website lists them, not checked against each database; for Web of Science editions the records above apply.
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 4.16LetPub ·
- CiteScore 2026-06
- 7.7LetPub ·
- SJR 2026-06
- 1.46LetPub ·
- SNIP 2026-06
- 1.35LetPub ·
- h-index
- 28LetPub ·
- h-index
- 85OpenAlex ·
- i10-index
- 1,281OpenAlex ·
- 2-year mean citedness
- 3.35OpenAlex ·
- Self-citation rate
- 2.4%LetPub ·
- Share of gold OA articles
- 99.43%LetPub ·
Volume
- Articles per year
- 107LetPub ·
Articles by year OpenAlex count · 2,361 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 80 | 80 | 22 |
| 2025 | 164 | 164 | 331 |
| 2024 | 138 | 138 | 925 |
| 2023 | 138 | 138 | 1,560 |
| 2022 | 79 | 79 | 1,561 |
| 2021 | 141 | 141 | 2,707 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with Crossref · to
123 daysMedian, submission to acceptance · P25–P75 83 days – 152 days
- Acceptance to online
- median 205 days (83 articles)
- Submission to online
- median 328 days
- Sample
- 81 articles with submission and acceptance dates (356 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- over 12 weeksLetPub ·
- Average acceptance (community reports)
- Fairly easyLetPub ·
- Peer review
- Double anonymous peer reviewPublisher website
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Fully open accessOpenAlex
Every article is open access; authors usually pay an article processing charge (APC).
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| Publisher website | USD 600 / USD 300 | — | — |
Other charges and waivers (author guidelines)
- Submission fee
- USD 600
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
What to prepare4 items from the author guidelines
- Abstract
- ≤ 250 words
- Keywords
- ≥ 3
- Reference style
- Vancouver
- Cover letter
- Required
Article types accepted4, with length limits
- case reportCase Reports are not encouraged and are considered only if justified by their unique significance or depth of studies on the case. The abstract should be unstru…main text ≤ 150 words · abstract ≤ 150 words · figures and tables ≤ 5 · references ≤ 15
- original articleOriginal Articles are the primary presentation mode of scientific communication in the journal. Acceptance of manuscripts is based on many factors, including th…Length not stated
- retractionRetractionJune 19, 2026 RETRACTION: Everolimus Plus Ku0063794 Regimen Promotes Anticancer Effects against Hepatocellular Carcinoma Cells through the Paradoxical…Length not stated
- review articleReview Articles and Editorials are usually solicited by the Editor-in-Chief. However, unsolicited Review Articles will also be considered for publication, in wh…Length not stated
Policy excerpts from the journal's websiteAI use, Authorship, Conflicts of interest, Data availability, License & copyright, Open access, Peer review, Trial registration / reporting guidelines
- AI use Use of Artificial Intelligence (AI)-assisted Technologies
The journal has adopted policies, as specified by the ICMJE, regarding the use of AI in the preparation of materials intended for publication in the journal. Generative AI, including language models, chatbots, image creators, machine learning, or similar technologies, may be employed to enhance readability and language accuracy in scientific writing. However, chatbots or other AI-assisted technolo…
Source ↗Publisher website ·- Authorship Authorship
Authorship credit should be based on 1) substantial contributions to conception and design, acquisition of data, or analysis and interpretation of data; 2) drafting the article or revising it critically for important intellectual content; 3) final approval of the version to be published; and 4) agreement to be accountable for all aspects of the work in ensuring that questions related to the accura…
Source ↗Publisher website ·- Conflicts of interest 5) Conflicts of Interest
All potential conflicts of interest must be stated within the manuscript. This pertains to relationships with pharmaceutical companies, biomedical device manufacturers, or other corporations whose products or services are related to the subject matter of the article. Such relationships include, but are not limited to, employment by an industrial concern, ownership of stock, membership on a standin…
Source ↗Publisher website ·- Data availability Data Sharing
CRT accepts the ICMJE recommendations for data sharing statement policy (https://www.icmje.org/recommendations/browse/publishing-and-editorial-issues/clinical-trial-registration.html). To foster transparency, we encourage authors to state the availability of their data in your submission. Subject to ethical and legal considerations, authors are encouraged to: · Upload research data during the subm…
Source ↗Publisher website ·- License & copyright Copyright
All published papers become the permanent property of the Korean Cancer Association. Upon acceptance of the manuscript, the authors will be required to sign a statement confirming that the manuscript contains no material the publication of which violates any copyright or other personal or proprietary right of any person or entity.
Source ↗Publisher website ·- Open access Open Access License
CRT is an open access journal. Articles are distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited. Authors do not need permission to use tables or figures published in CRT in othe…
Source ↗Publisher website ·- Peer review 3. PEER REVIEW PROCESS
CRT adopts a double-blind peer review, where author and reviewer identities are concealed from each other but visible to the decision-making editor. Reviewers interact only with an editor, ensuring an independent review. The acceptance criteria for all papers are based on the quality and originality of the research and its clinical and scientific significance. An initial decision will normally be …
Source ↗Publisher website ·- Trial registration / reporting guidelines Reporting Guidelines for Specific Study Designs
For specific study designs, such as randomized control studies, studies of diagnostic accuracy, meta-analyses, observational studies and non-randomized studies, it is recommended that the authors follow the reporting guidelines listed in the following table. Initiative Type of study CONSORT(Source) Randomized controlled trialshttps://www.equator-network.org/reporting-guidelines/consort/ STARD(Sour…
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- Korean Cancer Association
- Country or region
- SOUTH KOREA
- Language
- English
- ISSN
- 1598-2998
- Electronic ISSN
- 2005-9256
- Society / sponsor
- Korean Cancer Association Korean Society of Medical Oncology Korean Association for Lung Cancer
- Latest issue on the website
- Volume 58 (July 2026)
- Official links
- Journal homepage ↗OpenAlex
- Submission system ↗LetPub
FAQ
Frequently asked questions about Cancer Research and Treatment
What CAS zone is Cancer Research and Treatment in?
In the 2025 upgraded edition of the CAS Journal Ranking, Cancer Research and Treatment is in Zone 2 of Medicine, and in Zone 3 of the minor category Oncology. In the 2026 Xinrui edition it is in Zone 3 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Cancer Research and Treatment?
The latest impact factor listed by LetPub is 4.16; CiteScore 7.7, h-index 85.
How long does peer review take at Cancer Research and Treatment?
Based on the dates recorded on 81 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 123 days (interquartile range 83–152 days); authors report an average review time of over 12 weeks; the community-reported acceptance is “Fairly easy”. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
What are the manuscript requirements of Cancer Research and Treatment?
According to the journal's author guidelines: Abstract: ≤ 250 words; Keywords: ≥ 3; Reference style: Vancouver; Cover letter: Required. A model extracted these from the author guidelines and each was checked against the text; check the latest version on the journal's website before submitting.
Where are the editorial board members of Cancer Research and Treatment based?
Of the 29 board members whose country the journal's board page names, 1 (about 3%) are in mainland China; the countries named most often are South Korea (21), United States (4) and Japan (2). Counted from the institutions listed on the board page; for reference only.
Which databases index Cancer Research and Treatment?
According to LetPub and DOAJ records, Cancer Research and Treatment is indexed in SCIE and Scopus. The journal's website also lists MEDLINE, PMC and CAS; that list has not been checked against each database.
Is Cancer Research and Treatment open access, and what is the APC?
Cancer Research and Treatment is a fully open-access journal. APC about USD 600.
Sources and updates
The facts on this page come from LetPub, Publisher website, OpenAlex; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-26). Last updated: .